News

Public · Published

Citigroup maintains Krystal Biotech at Buy, lowers price target to $412 from $416

Citigroup kept its Buy rating on Krystal Biotech but lowered its price target to $412 from $416, a 1.0% decrease. That target implies 39.2% upside from the November 2 close of $295.90.

Published:

Updated:

What happened

Citigroup kept its Buy rating on Krystal Biotech but lowered its price target to $412 from $416, a 1.0% decrease. That target implies 39.2% upside from the November 2 close of $295.90.

Confirmed

Global impact / market context

A small cut to a Buy price target still signals Citigroup expects the stock to rise well above its last close. Investors watching analyst targets may treat the trim as a minor adjustment rather than a change in view on the company.

Analyst inference

Other recent analyst notes set targets between $361 and $380, all above the $295.90 close. Citigroup's $412 target is the highest of these, which suggests its analysts see more room for gains than peers covering the same stock.

Analyst inference

What to watch

  1. Citigroup's $412 target implies 39.2% upside from the November 2 close of $295.90, so watch whether the stock moves toward that level over time. Confirmed
  2. Watch whether other analysts change their Krystal Biotech price targets, since the three recent notes ranged from $361 to $380 and a shift could show changing views. Proposed
  3. Watch the company's upcoming results and any pipeline news, because analyst targets rest on future revenue and profit expectations that new data could raise or lower. Analyst inference

Evidence

  • Original source link unavailable